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Abstract 
Background and Aim: In 2 Japanese neonatal cholestatic patients with 3-oxo-4-steroid 
5-reductase deficiency who had diagnosed as mutations of SRD5B1 gene and detected unusual 
bile acids such as elevated 3-oxo-4 bile acids in serum and urine using gas 
chromatography-mass spectrometry, we discussed about effect of oral chenodeoxycholic acid 
treatment.  
Patients and Methods: We evaluated the laboratory data, bile acid analysis, and SRD5B1 gene 
analysis from 2 patients with neonatal cholestasis. SRD5B1 gene and bile acid analysis are 
required using genomic DNA of peripheral lymphocyte and gas chromatography-mass 
spectrometry of serum and urine from 2 patients, respectively. Diagnosis and treatment of these 
2 patients were retro- and prospectively investigated. 
Results: Two patients were diagnosed as 3-oxo-4-steroid 5-reductase deficiency by SRD5B1 
gene and bile acid analysis. One was novel heterozygote (R266Q) and the other was compound 
hetrozygote (G223E/R261C). Chenodeoxycholic acid treatment was effective to improve liver 
dysfunction and to reduce unusual bile acids such as 7-hydroxy- and 
7,12-dihydroxy-3oxochol-4en-24-oic acids in serum and urine. 
Conclusion: Primary bile acid treatment using chenodeoxycholic acid is effective for these 
patients in the early neonatal period before the late stage of chronic cholestatic liver dysfunction. 
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Introduction 
In 1988, Clayton et al reported that, in pediatric patients with severe liver disease such as 
cholestatic disease with cirrhosis and fumarylacetoacetase deficiency, the major unusual bile 
acids were 3-oxo-4 bile acids, such as 7-hydroxy- and 
7,12-dihydroxy-3oxochol-4en-24-oic acids (Clayton et al. 1988). At the same time, 
3-oxo-4-steroid 5-reductase (5-reductase) deficiency was also described for the first time by 
Setchell et al (Setchell et al. 1988). This inborn error of bile acid synthesis is very rare disease 
and is autosomal recessive inheritance. The main findings of 5-reductase deficiency were the 
normal or the slightly elevated concentration of total bile acids (TBA) and -glutamyltranferase 
(GGT) in serum, elevated conjugated hyper bilirubinemia and alanine aminotransferase (ALT), 
and fatty stools. During the course of synthesis of bile acids from cholesterol, named classical 
pathway, if activity of 5-rductase enzymes decreased, reduced synthesis of primary bile acids 
and increased synthesis of 3-oxo-4 bile and allo-bile acids.  
    Lemonde et al and Gonzales et al reported SRD5B1 (AKR1D1) gene analysis in 
5-rductase deficiency on chromosome 7q32-33 in 2003 and 2004, respectively (Lemonde et al. 
2003,,Gonzales et al. 2004). According to these 2 reports, mutation in the SRD5B1 gene were 
identified all 5 patients, 3 homozygous mutations and 2 compound heterozygous mutations 
(Lemonde et al. 2003,,Gonzales et al. 2004). Recently, we also reported 2 heterozygous 
mutations in patients with 5-rductase deficiency that was diagnosed by bile acid analysis using 
gas chromatography-mass spectrometry (GC-MS) (Ueki et al. 2009). 
    We here reported to diagnose 2 infants, 6 months old Japanese boy, and 9 months old 
Japanese girl, with 5-rductase deficiency resulting from one heterozygous and the other 
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compound heterozygous mutations in the SRD5B1 gene. Moreover, we discuss about clinical 
effect of oral chenodeoxycholic acid (CDCA) treatment of these 2 patients with 5-reductase 
deficiency. 
 
Patients and Methods  
Patient report 
Patient 1: A male Japanese infant was delivered at 37 weeks gestational age an uneventful 
pregnancy. The parents were not consanguineous and were healthy, without liver disease. At 
birth, he was noticed abdominal distension and metabolic acidosis. We detected abdominal free 
air by abdominal X-ray and CT scanning. Therefore, we performed operation the suspected 
gastrointestinal perforation at second days after birth. After operation at Saitama Medical 
University Hospital, he was diagnosed meconium peritonitis due to perforation of jejunum with 
neonatal intussuception. 
    Thereafter, he persistence jaundice until at 6 months of age. We performed the serial 
technetium-99m (99mTc)-DISIDA cholescintigraphy and liver biopsy at 2 and 3 months of age, 
respectively. No cholescintigraphy revealed visualization of intestinal radioactivity. His liver 
microscopic findings revealed giant cell transformation and consistent with fibrosis showing 
wide fibrotic bands at portal areas.  
    His laboratory studies disclosed an aspartate aminotransferase (AST) concentration in 
serum of 344 U/L (normal range <37); ALT, 441 I/L (<31); and total/direct bilirubin, 4.4/3.4 
mg/dL (<1.2/0.4). GGT concentration in serum was 46 U/L (<52); and we did not examine 
serum TBA at admission. We suspected the inborn errors of bile acid synthesis from above data, 
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and analyzed serum and urine bile acids using GC-MS, as results of bile acid analysis showed 
Table 1. From results of bile acid analysis, we suspected the 5-reductase deficiency. At that 
time he was received ursodeoxycholic acid (UDCA) treatment. 
Patient 2: A female Japanese infant with a birth weight of 2832 g was delivered by spontaneous 
vaginal delivery without complications at a gestational age of 38 weeks, after an uneventful 
pregnancy, her mother’s first. The parents were not consanguineous and were healthy, without 
liver disease. 
    Progressive jaundice became apparent in the infant at the age of 3 months. At 6 months, the 
patient was referred to Kyushu University Hospital because of jaundice and liver dysfunction. 
    On physical examination, growth and development were within normal range. No 
dysmorphic features were present. Hepatomegaly and jaundice were noted. Neurologic findings 
were normal. Stools were gray. Initial laboratory results included serum concentration of AST, 
315 U/L; ALT, 229 U/L; alkaline phosphatase, 2717 U/L (115 to 359); total/direct bilirubin, 
6.3/3.6 mg/dL; albumin, 4.8 g/dL (4.0 to 5.0); total cholesterol, 216 mg/dL (128 to 219); 
prothrombin time, 14.8 seconds (10.0 to 13.5); and blood ammonia, 66 g/dL (<66). Serum 
GGT was 61 U/L and serum TBA, 5.2 mol/L (<10). Other causes of liver disease such as 
autoimmune hepatitis, chronic viral hepatitis, and other metabolic conditions were excluinded 
by appropriate investigations. Abdominal ultrasonography showed a visible gallbladder and 
hepatomegaly; no choledochal cyst, bile duct dilation, or ascites was demonstrated. Serial 
technetium-99m (99mTc)-DISIDA cholescintigraphy indicated that tracer entered the intestine. 
We suspected the inborn errors of bile acid synthesis from above data, and analyzed serum and 
urine bile acids using GC-MS at 9 months of age, as results of bile acid analysis showed Table 1. 
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From results of bile acid analysis, we suspected the 5β- reductase deficiency. 
 
Qualitative and quantitative bile acid analysis 
The serum and urine samples were collected and stored at -25℃ until analysis. The 
concentrations of the individual bile acids in the urine were corrected for the creatinine (Cr) 
concentration and expressed as mol/mmol of Cr.  
    After we synthesized some specific unusual bile acids, such as 3-hydroxy-5 (Tohma et al. 
1986), 3-oxo-4 (Leppik 1983) and allo-bile acids (Iida et al. 1993), as seen in inborn errors of 
bile acid synthesis, we routinely analyzed the bile acids in the urine and serum by GC-MS using 
selected ion monitoring of the characteristic fragments of the methyl ester-dimethylethylsilyl 
ether-methoxime derivatives of the bile acids as described previously (Kimura et al. 1999), after 
enzymatic hydrolysis (choloylglycine hydrolase 30 units) and solvolysis (sulfatase 150 units; 
Sigma Chemical Co., St Louis, MO, USA). 
    Two patients in this study had the bile acids in their serum and urine analyzed using 
GC-MS on admission and during bile acid treatment. 
 
Genetic analysis 
With informed consent, SRD5B1 gene analysis was performed using genomic DNA from 
peripheral lymphocytes from 2 patients, their parents, as well as 50 healthy individuals. DNA 
fragments spanning the 9 coding regions and exon-intron junctions of the SRD5B1 gene were 
amplified by polymerase chain reaction (PCR) using Gene Taq (Nippon Gene, Toyama, Japan) 
and 9 sets of primers to obtain DNA fragments of the optimal length for direct sequence analysis 
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(Ueki et al. 2009). 
    After enzyme processing with ExoSAP-IT (USB, Cleveland, OH), direct sequencing of the 
amplified PCR products was carried out with a DTCS Quick Start Kit (Beckman Coulter, 
Fullerton, CA) according to the manufacturer’s protocol, using the same primers as for PCR 
amplification. The sequencing reaction product was analyzed electrophoretically using an 
SEQ2000XL analyzer (Beckman Coulter, CA). 
    After the 3 putative mutations were found in the patients, their parents and 50 healthy 
individuals were screened for these 3 mutations by direct sequence analysis. 
    All studies were undertaken with permission from The Ethical Committee of Kurume 
University School of Medicine.  
 
Results 
Biochemical identification of an inborn error of bile acid synthesis 
Patient 1: He had jaundice since early neonatal period, especially after operation. So far, 
condition of this patient was stable due to UDCA (7.5 mg/kg/day) treatment.  UDCA treatment 
was effective for liver dysfunction, such as elevated ALT and total bilirubin. After diagnosis, we 
started combined UDCA and CDCA (5 mg/kg/day) treatment. Liver dysfunction was improved 
by combined UDCA and CDCA treatment completely (Fig 1-A). Serum value of total bilirubin 
was decreased to normal range before decreased that of ALT. While, concentrations of 3-oxo-4 
bile acids in serum and urine were not reduced by UDCA treatment. After combined UDCA and 
CDCA treatment, serum 3-oxo-4 bile acids gradually decreased to not detectable, less than 1 
mol/L. While urinary 3-oxo-4 bile acids decreased after fluctuations. Since UDCA treatment 
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stopped at 14 months of age, liver function and bile acid profiles in serum and urine were stable 
by CDCA mono-treatment. 
Patient 2: She was received UDCA (7 mg/kg/day) treatment at 8 months of age but no 
improvement of clinical symptoms and liver dysfunction. After diagnosis, we started combined 
UDCA (10 mg/kg/day) and CDCA (10 mg/kg/day) treatments at 9 months of age. Liver 
dysfunction, ALT and serum TBA, increased but 3-oxo-4 bile acids in serum decreased. All 
most serum TBA is CDCA. While concentrations of TBA and 3-oxo-4 bile acids in urine were 
increased respectively (Fig. 1-B). Then we reversed dose of CDCA from 10 to 5 mg/kg/day, 
thereafter, combined UDCA (10 mg/kg/day) and CDCA (5 mg/kg/day) treatment was effective 
for liver dysfunction. Serum value of total bilerubin was also decreased to normal range before 
decreased that of ALT as well as patient 1 and concentrations of TBA and 3-oxo-4 bile acids in 
serum and urine were gradually decreased. Clinical course of liver dysfunction and bile acid 
profiles in serum and urine were gradually decreased by CDCA mono-treatment at 15 months 
old of age. At elevated ALT and TBA in serum and urine, we detected elevated cytomegalovirus 
(CMV) antibodies. EIA units of serum IgM antibodies against CMV (< 0.8) were under 0.34 at 
6 months of age and elevated to 1.27 at 11 months of age. The serum IgG antibodies (< 0.2) at 6 
months of age were under 2.0 and elevated to 28.0 at 11 months of age. 
 
Identification of SRD5B1 gene defects 
We identified 1 novel mutation and 2 reported mutations in these 2 patients. 
Patient 1: A single heterozygous mutation, novel, was found in exon 7, at nucleotide number 
866, representing a G-to-A substitution, causing an amino acid change from arginine to 
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glutamine (R266Q). The mutation was detected in heterozygous form in the mother, but absent 
in the father and controls (Fig. 2). 
Patient 2: Two heterozygous mutations, previously reported, were found. One was detected in 
exon 6, at nucleotide number 737, representing a G-to-A substitution, causing an amino acid 
change from glycine to glutamic acid (G223E). G223E was detected in heterozygous form in 
the father, but absent in the mother and 50 healthy individuals. The other was detected in exon 7, 
at nucleotide number 850, representing a C-to-T substitution, causing an amino acid change 
from arginine to cysteine (R261C). R261C was detected in heterozygous form in the mother, 
but absent in the father and controls (Fig. 3). 
    The above nucleotide numbers indicating positions of individual mutations are based on 
GenBank accession no. NM_0059892. 
 
Discussion 
In our 2 patients with 5β-reductase deficiency who had SRD5B1 mutation, CDCA treatment 
was effective because of improved liver dysfunction and reduced unsaturated ketonic bile acids 
in serum and urine. Oral bile acid treatment such as cholic acid (CA) was safe and effective 
intreating most common inborn errors of bile acid synthesis, including 5β-reductase deficiency 
(Gonzales et al. 2009). CA treatment may be better because activates negative feedback 
regulation of bile acid synthesis to inhibit production of hepatotoxic metabolites and is not itself 
hepatotpxic better than CDCA. However CA is not available for clinical use in Japan. 
According to previous report (Clayton et al. 1996), combined CA and CDCA treatment for 
5β-reductase deficiency was also used. We suggested that oral bile acid treatment using CDCA 
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mono-treatment is effective for patient with 5β-reductase deficiency. 
    In bile acid analysis during combined UDCA and CDCA treatment, external UDCA was 
detected in urine more than that in serum, while external CDCA was detected in serum more 
than that in urine (data not shown). We think that hydrophilic UDCA may be prone to excrete 
from kidney to urine by multidrug resistance-related protein 4 after transport from hepatocytes 
to blood by multidrug resistance-related protein 4 in the basolateral membrane (Wagner et al. 
2005, Marschall et al. 2005, Stapelbroek et al. 2010). Unsaturated ketonic bile acids, 3-oxo-4 
bile acids, were detected in urine more than in serum. 3-Oxo-4 bile acids were across the 
basolateral membrane via multidrug resistance-related protein 3 from hepatocytes to blood 
(Tamaguchi et al. 2010). Thereafter, 3-oxo-4 bile acids excrete to urine immediately by some 
bile acid transporter. As the results, we may be detected large amounts of urinary 3-oxo-4 bile 
acids in this disease. 
    In spite of normal liver function, we detected 3-oxo-4 bile acids in serum and urine, 
especially urine. We speculate that negative feedback via 5mg/kg/day of CDCA may be 
incomplete. However if CDCA dose increase, liver function may be aggravated by some 
possibility. CDCA dose such as 10 mg/kg/day may be very effective negative feedback to 
cholesterol 7-hydroxylase via the farnesoid X receptor (Gonzales et al. 2009). Therefore, we 
should be very carefully following these patients. Best following liver functional test may be 
analysis of bile acid in serum and urine, marker of fibrosis such as type IV collagen 7s domain, 
and especially pathologic findings by liver biopsy. However, fluctuations of urinary 3-oxo-4 
bile acids may be not always showed stage of disease. Because since we analyze urinary bile 
acid using spot sample of serum and urine, we do not deny the relation of the diet. Moreover, 
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some liver disease reduced activity of 5β-reductase, such as metabolic, viral (Clayton et al. 1988, 
Kimura et al. 1998), and drug induced hepatitis. Therefore, it is very carefully to affect the viral 
infection such as cytomegaro virus infection in neonatal period or to be used medicine. Actually 
we speculated that 3-oxo-4 bile acids in serum and urine of our patient 2 were increased by 
itself hepatotoxic of CDCA (Fig. 1-B) or effect of CMV hepatitis.. 
    Interestingly, duration until become to normalizing laboratory data during oral bile acid 
treatment using combined UDCA and CDCA treatment or CDCA mono-treatment, of patient 
with 5β-reductase deficiency spent long-term period more than that of patient with 
3-hydroxy-5-C27-steroid dehydrogenase/isomerase deficiency from our experience (Yamato 
et al. 2001, Mizuochi et al. 2010). From these results, we recommended that treatment of patient 
with 5β-reductase deficiency should be start the oral bile acid treatment in the early neonatal 
period before the late stage of chronic cholestatic liver dysfunction because of 5-reductase 
deficiency will be development to cholestatic liver failure until less than about 10 months of age 
(Gonzales et al. 2004, Ueki et al. 2009). 
    The human SRD5B1 gene contains 9 coding exons corresponding to 326 amino acids; so 
far, 7 distinct mutations causing 5β-reductase deficiency have been reported (Lemonde et al. 
2003,,Gonzales et al. 2004, Ueki et al. 2009). This enzyme deficiency has been characterized as 
showing autosomal recessive transmission. Here we describe genetic analysis of the SRD5B1 
gene in 2 patients with 5-reductase deficiency, and identified 1 novel mutation (R266Q) and 2 
reported mutations (G223E and R261C) (Gonzales et al. 2004, Ueki et al. 2009, Drury et al. 
2010). Screenibg for the potentially informative mutation R266Q was undertaken for 50 healthy 
individuals, but this mutation was absent in all of them. Moreover, the R266Q mutation was 
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predicted to probably have an adverse effect (score, 0.995) with Polymorphism Phenotyping 
version 2 (Adzhubei et al. 2010). Accordingly, we believe that the R266Q mutation may have 
contributed to a loss of function of 5-reductase in our patients. Patient 1 has only a single 
heterozygous mutation (R266Q) in one allele from his mother. We would still suspect that 
patient 1 with a heterozygous mutation of the SRD5B1 gene may have a mutation in another 
allele and he is compound heterozygote. Patient 2 has two heterozygous mutations 
(G223E/R261C). The patient 2 received 1 allele with G223E mutation from the father, and the 
other allele with R261C from the mother, making her a compound heterozygote for the SRD5B1 
gene. 
    In conclusion, we diagnosed 2 patients with 5-reductase deficiency, one had heterozygous 
and the other had compound heterozygous mutations in SRD5B1 gene. Primary bile acid 
treatment using CDCA (5 mg/kg/day) is effective for these patients with 5β-reductase deficiency 
in the early neonatal period before the late stage of chronic cholestatic liver dysfunction. 
 14
References 
Adzhubei IA, Schmidt S, Peshkin L, Pamensky VE, Gerasimava A, Bork P,  
Kondrashov AS Sunyaev SR. A method and server for predicting damaging 
missense mutations Nat Methods 2010;7:248-249. 
Clayton PT, Patel E, Lawson AM, Carruthers RA, Tanner MS, Strandvik B, Egestad B, Sjövall J. 
3-Oxo-4 bile acids in liver disease. Lancet 1988;1:1283-1284. 
Clayton PT, Mills KA, Johnson AW, Barabino A, Marazzi MG. 4-3-Oxosteroid 
5-reductase deficiency: Failure of ursodeoxycholic acid treatment and 
response to chenodeoxycholic acid plus cholic acid. Gut 1996;38:623-628. 
Drury JE, Mindnich R, Penning TM. Characterization of disease-related 
5-reductase (AKR1D1) mutations reveals their potential to cause bile acid 
deficiency. J Biol Chem 2010;285;24529-24537. 
Gonzales E, Cresteil D, Baussan C, Dabadie A, Gerhardt M-F, Jacquemin E. SRD5B1 
(AKR1D1) gene analysis in 4-3-oxosteroid 5-reductase deficiency: evidence for 
primary genetic defect. J Hepatol 2004;40:716-718. 
Gonzales E, Gerhardt MF, Fabre M, Setchell KDR, Davit-Spraul A, Vincent I, Heubi JE, 
Bernard O, Jacquemin E. Oral cholic acid for hereditary defects of primary bile acid 
synthesis: A safe and effective long-term therapy. Gastroenterology 2009;137:1310-1320. 
Iida T, Nishida S, Chang FC, Niwa T, Goto J, Nambara T. Potential bile acid metabolism. XXI. 
A new synthesis of allochenodeoxycholic and allocholic acids. Chem Pharm Bull 
1993;41:763-765. 
Kimura A, Suzuki M, Murai T, Kurosawa T, Tohma M, Sata M, Inoue T, Hoshiyama A, 
 15
Nakashima E, Yamashita Y, Fujisawa T, Kato H. Urinary 7-hydroxy-3-oxochol-4-en 
24-oic and 3-oxochola-4,6-dien-24-oic acids in infants with cholestasis. J Hepatol 
1998;28:270-279. 
Kimura A, Mahara R, Inoue T, Momura Y, Murai T, Kurosawa T, Tohma M, Noguchi K, 
Hoshiyama A, Fujisawa T, Kato H. Profile of urinary bile acids in infants and children: 
Developmental pattern of excretion of unsaturated ketonic bile acids and 7-hydroxylated 
bile acids. Pediatr Res 1999;45:603-609. 
Lemonde HA, Custard EJ, Bouquet J, Duran M, Scambler PJ, Clayton PT. Mutation in SRD5B1 
(AKR1D1), the gene encoding 4-3-oxosteroid 5-reductase, in hepatitis and liver failure 
in infancy. Gut 2003;52:1494-1499. 
Leppik RA. Improved synthesis of 3-keto, 4-ene-3keto-, and 4,6-diene-3-keto bile acids. 
Steroids 1983;41:475-484. 
Marschall H-U, Wagner M, Zollner G, Fickert P, Diczfalusy U, Gumhold J, Silbert D, 
Fuchsbichler A, Benthin L, Grundstrom R, Gustafsson U, Sahlin S, Einarsson C, Trauner 
M. Complementary stimulation of hepatobiliary transport and detoxification systems by 
rifampicin and ursodeoxycholic acid in humans. Gastroenterology 2005;129:476-485. 
Mizuochi T, Kimura A, Ueki I, Takahashi T, hashimoto T, Takao A, Seki Y, Takei H, Nittono H, 
Kurosawa T, Matsuishi T. Molecular genetic and bile acid profiles in two Japanese 
patients with 3-hydroxy-5-C27-steroid dehydrogenase/isomerase deficiency. Pediatr 
Res 2010;68:258-263. 
Setchell KDR, Suchy FJ, Welsh MB, Zimmer-Nechemias L, Heubi J, Balistreri WF. 
4-3-Oxosteroid 5-reductase deficiency described in identical twins with neonatal 
 16
hepatitis. J Clin Invest 1988;82:2148-2157. 
Stapelbroek JM, von Erpecum KJ, Klomp LWJ, Houwen RHJ. Liver disease associated with 
canalicular transport defects: Current and future therapies. J Hepatol 2010;52:258-271. 
Tohma M, Mahara R, Takeshita H, Kurosawa T. A convenient synthesis of 3,12-, 3,7-, and 
3,7-dihydroxy-5-cholen-24-oic acids: unusual bile acids in human biological fluids. 
Steroids 1986;48:331-338. 
Ueki I, Kimura A, Chen H-L, Yorifuji T, Mori J, Itoh S, Maruyama K, Ishige T, Takei H, 
Nittono H, Kyrosawa T, Kage M, Matsuishi T. SRD5B1 gene analysis needed for the 
accurate diagnosis of primary 3-oxo-4-steroid 5-reductase deficiency. J Gastroenterol 
Hepatol 2009;24:776-785. 
Wagner M, Trauner M. Transcriptional regulation of hepatobiliary tranport systems in health 
and disease: Implications for a rationale approach to the treatment of intrahepatic 
cholestasis. Ann Hepatol 2005;4:77-99. 
Yamaguchi K, Murai T, Yabuuchi H, Kurosawa T. Measurement of transport 
activities of bile acids in human multidrug resistance-associated protein 3 
using liquid chromatography-tandem mass spectrometry. Anal Sci 
2010;26:317-323. 
Yamato Y, Kimura A, Murai T, Yoshimura T, Kurosawa T, Terazawa S, Takao A, Maeda K, 
Nakashima E, Yamashita Y, Kato H. 3-Hydroxy-5-C27-steroid dehydrogenase 





Figure 1. Clinical course of patient 1 (A) and patient 2 (B). 
Responses of the serum alanine aminotransferase (ALT; closed circle), total bilirubin (T Bil; 
open circle), serum total bile acids (s-TBA; closed square), serum 3-oxo-4 bile acids 
(s-3-oxo-4; open square), urine total bile acids (u-TBA; closed triangle), and urine 3-oxo-4 
bile acids (u-3-oxo-4; open circle) to treatment with combined ursodeoxycholoc acid (UDCA) 
and chenodeoxycholic acid (CDCA) treatment or CDCA mono-treatment are shown.  
 
Figure 2. Pedigree for patient 1 shown with genomic DNA sequences in exon 7 of the 
SRD5B1 gene in this patient, his parents, and a control. 
The arrow in exon 7 identifies G/A in the patient and his mother, but G in his father and a 
control subject. The reverse strand sequence shows the same result. This represents a 
CGA-to-CAA mutation, affecting arginine at position 266, where it is replaced by glutamine.  
 
Figure 3. Pedigree for patient 2 shown with genomic DNA sequences in exons 6 and 7 of 
the SRD5B1 gene in this patient, his parents, and a control. 
The arrow in exon 6 identifies G/A in the patient and her father, but G in her mother and a 
control subject. The reverse strand sequence shows the same result. This represents a 
GGG-to-GAG replacing, affecting glycine at position 223, where it is replaced by glutamic acid. 
The arrow in exon 7 identifies C/T in the patient and her mother, but C in her father and a 
control subject. The reverse strand sequence shows the same result. This represents a 
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Table 1. Bile acid analysis using GC-MS in 2 patients with 3-oxo-4-steroid 5-reductase deficiency 
                                                          Patient 1                    Patient 2  
                                                      (6 months of age)              (9 months of age) 
Serum (mol/L)  
Cholic acid n.d. n.d. 
Chenodeoxycholic acid 0.1 n.d. 
Deoxycholic acid 0.2 n.d. 
Lithocholic acid n.d. n.d. 
Ursodeoxycholic acid 1.5 n.d. 
Allo-cholic acid n.d. n.d. 
Allo-chenodeoxycholic acid 0.9 n.d. 
7,12-Dihydroxy-3-oxo-4-cholen-24-oic acid 0.3 14.4 
7-Hydroxy-3-oxo-4-cholen-24-oic acid 1.7 10.7 
Others 0.6 2.3 
Total bile acids 5.3 27.4 
Urine (mol/mmol Cr) 
Cholic acid 0.2 n.d. 
Chenodeoxycholic acid n.d. n.d. 
Deoxycholic acid 0.1 n.d. 
Lithocholic acid n.d. n.d. 
Ursodeoxycholic acid 0.9 n.d. 
Allo-cholic acid 0.8 n.d. 
Allo-chenodeoxycholic acid n.d. n.d. 
7,12-Dihydroxy-3-oxo-4-cholen-24-oic acid 121.1 37.5 
7-Hydroxy-3-oxo-4-cholen-24-oic acid 2.8 21.4 
Others n.d. 0.2 
Total bile acids 125.9 59.1 
n.d., not detected. 
